ArticleJournal of surgical case reports2026
Conversion surgery after chemoimmunotherapy for esophageal squamous cell carcinoma with gastric intramural metastasis: a case report and the literature review.
Article in Journal of surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Esophageal intramural metastasis from adenocarcinoma of esophagogastric junction: a case report and literature review.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have recently emerged as promising first-line treatments. Among stage IVb esophageal squamous cell carcinoma (ESCC) cases, gastric wall metastasis is rare, and conversion surgery after ICI therapy in such cases is extremely uncommon. We report a case of stage IVb ESCC with gastric intramural metastasis (IM) successfully treated with conversion surgery following ICI-based chemoimmunotherapy, along with a review of the relevant literature. A 73-year-old man was diagnosed with ESCC with gastric IM (Mt, SCC, cT3brN1M1b [IM-St], stage IVb). He received three cycles of combination immunochemotherapy with cisplatin, 5-fluorouracil, and pembrolizumab. Conversion surgery was subsequently performed. Pathological examination demonstrated a complete response, with no residual carcinoma in either the esophagus or the gastric wall. The patient remains recurrence-free 8 months postoperatively. Further studies are warranted to clarify the optimal criteria for assessing ICI treatment response and determining indications for conversion surgery in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.